Shares of GlaxoSmithKline were down nearly 8% on Monday after the British company announced that it has agreed to buy Tesaro, a cancer specialist company for $4.16 billion. New CEO of GSK, Emma Walmsley said to reporters, “This is an example of us executing on what we said we were going to do … to … Continue reading “GSK Sinks as It Agrees to Buy Tesaro for Around $4 Billion”
Tag: TSRO
Biotech & Pharma
Tesaro (TSRO) Shares Double On Cancer Drug Success
You know champagne bottles are being popped open when your cancer drug treatment trial ends…
June 29, 2016